ZERO’s Medical Advisory Board provides strategic guidance and direction for our research investment and educational resources and programs. Their expertise spans everything from clinical and laboratory research to surgery and other disciplines and specialties. They actively contribute to our programs and events and serve as our ambassadors in communities across the country.
Alicia Morgans, M.D., M.P.H. (Chair)
The Feinberg School of Medicine, Northwestern University
Dr. Morgans is an Associate Professor at the The Feinberg School of Medicine at Northwestern University. She specializes in the treatment of genitourinary malignancies, including cancers of the prostate, bladder, testis (germ cell) and penis. She received a bachelor’s degree with honors in biology before going to medical school at the University of Pennsylvania School of Medicine. She then went on to complete a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Morgans completed a fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston, before becoming an Assistant Professor of Medicine at Vanderbilt University Medical Center. She also has achieved a Masters in Public Health.
Dr. Morgans’ research focus is on improving care and patient outcomes in advanced prostate cancer. Her research investigates the side effects of cancer treatment (including the prevention, diagnosis of, and treatment of these effects) and treatment decision-making among men with advanced prostate cancer. She also has an interest in supporting clinical research of novel treatments for genitourinary malignancies. Dr. Morgans is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group. She also serves as Vice Chair of ZERO’s Board of Directors and is the Chair of the Medical Advisory Board.
Dr. Morgans has contributed to numerous educational resources on behalf of ZERO. In a series of videos on advanced prostate cancer, Dr. Morgans discusses Understanding Late Stage Disease, Managing Pain, Clinical Trials, Improving Quality of Life, Treatment Options for Late Stage Disease, External Beam Radiation, radiopharmaceuticals, and Prostate Cancer and Bone Metastasis. In a recent webinar, “Advanced Prostate Cancer Treatments: Insights from a Provider and a Patient,” Dr. Morgans also explains the evolving landscape of treatment and management of advanced disease.
Tomasz Beer, M.D.
Knight Cancer Institute, Oregon Health & Science University
Dr. Tomasz Beer is a professor of medicine, clinician, and clinical, translational, and basic researcher in prostate cancer. He is an academic leader and senior healthcare executive responsible for strategic and operational leadership within an NCI-designated Comprehensive Cancer Center with responsibilities for oversight of the oncology service line, regional cancer network, interdisciplinary scientific programs, as well as shared scientific resources.
Tomasz M. Beer holds the Grover C. Bagby Endowed Chair for Prostate Cancer Research and serves as Professor of Medicine, Deputy Director at the Oregon Health & Science University Knight Cancer Institute and Chief Medical Officer of the Center for Early Detection Advanced Research (CEDAR) in Portland, Oregon. Dr. Beer leads the Prostate Cancer Research Program within the OHSU Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center. He received his medical degree from Johns Hopkins School of Medicine and completed his internship and residency in internal medicine and a fellowship in Hematology and Medical Oncology. Dr. Beer co-authored “Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies” and “Clinical Trials” and has led the global randomized trial of enzalutamide vs placebo, which served as the basis for a global change in the standard of care for advanced prostate cancer.
Learn more from Dr Beer on the subjects of “Clinical Trials” and “Current Treatments in Advanced Prostate Cancer: Side Effect Management and Clinical Trials.”
Nilay M. Gandhi, M.D.
Potomac Urology, Inova Alexandria Hospital
Nilay Gandhi, M.D. is a surgeon and urologist at Potomac Urology in Alexandria, VA, and serves as the Race Director of the ZERO Prostate Cancer Run/Walk – Capital Area. He is also the Vice Chair of Department of Surgery at Inova Alexandria Hospital and the co-founder of Doctomize, a physician’s electronic medical record consulting firm. He trained at the Brady Urological Institute at Johns Hopkins Hospital, where he developed his skills alongside many pioneers in the field.
In addition to his myriad published works, Dr. Gandhi also spoke about the importance of PSA testing and early detection at a United States Preventive Services Task Force briefing on Capitol Hill in 2018. He believes that a physician is not only a medical professional but a patient’s best advocate.
Leo Giambarresi, Ph.D.
American Urological Association, Director of Research (Retired)
Dr. Giambarresi received his BS in Biochemistry from the University of Massachusetts and his Ph.D. in Experimental Pathology from the University of Pittsburgh. After receiving his Ph.D., he was commissioned as a Lieutenant in the U. S. Navy Medical Service Corps. Early in his Navy career he focused on translational research related to support of military personnel, and in time he became more involved in military health science administration and education.
After 20 years, he retired at the rank of Commander specifically to assume a civilian position as the Program Manager of the Prostate Cancer Research Program, part of the DoD’s Congressionally Directed Research Programs. It is in this capacity that his passion for advancing progress in prostate cancer through research was ignited. This passion continued to grow in his subsequent position as the Director of Research at the American Urological Association (AUA). He retired after seven years at the AUA but continues his passion for advancing progress in prostate cancer as a member of ZERO’s Board of Directors and as a Scientific Review Officer for CSRA, the company that carries out peer review for the DOD research programs.
Elisabeth Heath, M.D., F.A.C.P.
Wayne State University School of Medicine
Dr. Heath is the Patricia C. and E. Jan Hartmann endowed chair in Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute and professor of Oncology and Medicine at Wayne State University School of Medicine in Detroit, Michigan. Dr. Heath has more than 26 years of experience and is a leading patient advocate for the metro Detroit community. At the ZERO Prostate Cancer Summit, she spoke about funding clinical trials and how that translates into better care for prostate cancer patients.
Benjamin H. Lowentritt, M.D., F.A.C.S.
Chesapeake Urology Associates and Director of the Minimally Invasive and Robotic Surgery Group at Chesapeake Urology, which is the ZERO Run/Walk founding partner in Baltimore, MD. Dr. Lowentritt is the former President of the Baltimore City Medical Society
Benjamin Lowentritt, M.D., F.A.C.S. is the Medical Director of the Prostate Cancer Care Program at Chesapeake Urology Associates, the ZERO Run/Walk founding partner in Baltimore, MD. He is also the Director of the Minimally Invasive and Robotic Surgery Group, and is the former President of the Baltimore City Medical Society.
Dr. Lowentritt trained at Baylor College of Medicine with a General Surgery Residency and Urology Residency at University of Maryland Medical System, followed by a fellowship in robotic, laparoscopic, and advanced endoscopic urology at Tulane University Medical Center. He specializes in minimally invasive techniques to treat urological conditions, and has been on the forefront of robotic urology procedures. He was also the first surgeon in Maryland to perform robot assisted surgery for bladder cancer. Dr. Lowentritt has also been selected as a “Super Doctor” by his peers in The Washington Post Magazine and as a “Top Doctor” in Baltimore magazine.
Dr.Lowentritt has contributed to any of ZERO’s educational resources, including videos on erectile dysfunction, incontinence, managing prostate cancer side effects, radiation treatment, active surveillance, “active surveillance is not watchful waiting,” genomic testing, early detection, and diagnosing prostate cancer.
Joanna Morales, Esq.
Joanna Fawzy Morales, Esq. is a cancer rights attorney, and CEO of Triage Cancer, a national, nonprofit organization providing education on the practical and legal issues that may impact individuals diagnosed with cancer and their caregivers, through events, materials, and resources. Mrs. Morales has spent 24 years working in the cancer community, including as an Adjunct Professor of Law at Loyola Law School, teaching Cancer Rights Law, and for the John Wayne Cancer Institute’s Psychosocial Care Program.
Mrs. Morales has presented hundreds of seminars on employment, insurance, financial, and advocacy issues and has co-authored a book on Cancer Rights Law for the American Bar Association. She’s been published in Psycho-Oncology, Coping with Cancer, Women, and other publications, including a book titled, “Work and Cancer Survivors.” In 2010, she was recognized by the Los Angeles Daily Journal as one of the Top 20 Attorneys in California Under the Age of 40.
Meredith Morgan, MSN
Urology Oncology Clinic, University of Michigan Comprehensive Cancer Center
Meredith Morgan is a board-certified acute care nurse practitioner currently working at Michigan Medicine Urology Oncology in the Rogel Cancer Center in Ann Arbor. She has also worked in prostate cancer survivorship at Vanderbilt University Medical Center and Weill Cornell Medical College/New York-Presbyterian Hospital. She has a Bachelor of Science in Psychology from the University of Georgia and a Master of Science in Nursing from Vanderbilt University.
Ms. Morgan discusses Living Beyond Prostate cancer in this webinar on “Survivorship.”
Kelvin Moses, M.D., Ph.D.
Vanderbilt University Medical Center
Dr. Kelvin A. Moses is an Assistant Professor of Urologic Surgery at Vanderbilt University Medical Center, and director of the Comprehensive Prostate Cancer clinic. He is a Phi Beta Kappa graduate of Morehouse College, and received his MD and PhD training at Baylor College of Medicine. He completed his Urology training at Emory University, followed by a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, where he served as Chief Administrative Fellow.
His clinical practice focuses on advanced prostate cancer, including conducting several clinical trials, as well as surgical management of advanced renal and testicular cancer. Dr. Moses’s research is focused on addressing health disparities in urologic cancers, determining the role of health literacy in patient interactions with the health care system, and optimal care for patients with metastatic and/or castrate-resistant prostate cancer. Dr. Moses also serves on ZERO’s Board of Directors.
Dr. Moses has contributed to numerous educational webinars, including: “Know Your Options: Latest Evidence for Early Use of Chemotherapy and Immunotherapy in Prostate Cancer“; “Treatment Options for Localized Prostate Cancer“; “Genomic Testing and Demystifying Your Diagnosis” and “Beyond the PSA: Genomic Testing in Localized Prostate Cancer.”
Rachel S. Rubin, M.D.
Dr. Rubin is a urologic surgeon and fellowship-trained sexual medicine specialist. She believes in comprehensive, multidisciplinary and customized care for patients and their partners suffering from sexual dysfunction. Her expertise includes erectile dysfunction, pelvic pain, penile curvature, low testosterone, low libido, urinary incontinence, and penile implants. Dr. Rubin is with IntimMedicine Specialists in Washington, D.C.
Charles J. Ryan, M.D.
University of Minnesota
Dr. Ryan is Director of Hematology, Oncology and Transplantation at the University of Minnesota. His research is aimed at developing new therapies for patients with advanced and recurrent prostate cancer. Specifically, Dr. Ryan is focused on the development of new hormonal and targeted therapies for prostate cancer, biomarkers defining disease aggressiveness, and strategies to maximize survivorship for men on long-term treatment.
Alison Sachs, MSW, CSW, OSW-C
Eisenhower Lucy Curci Cancer Center
Alison Sachs is the Director of Community Outreach and Cancer Support Services at Eisenhower Lucy Curci Cancer Center. She and her team are responsible for the development, design, implementation, budget and monitoring of community outreach, community education, disease prevention and health promotion programs, providing services to approximately 5,000 patients, family, and community members annually.
Ms. Sachs also serves as Adjunct Faculty of Graduate Medical Education, Family Practice at Eisenhower Medical Center and is a Field Instructor at the USC Graduate School of Social Work, the Cal State, San Bernardino, Graduate School of Social Work and the Simmons College Graduate School of Social Work. She is the former president of the Association Oncology Social Work and has published in the “Handbook of Oncology Social Work.”
Ms. Sachs also shared information on experiencing the holiday season with prostate cancer in ZERO’s webinar “The Meaning of the Season: Holidays With Prostate Cancer.”
Eric Shinohara, M.D., MSCI
Vanderbilt University Medical Center
Dr. Eric Shinohara is a board-certified radiation oncologist, Associate Professor, and Clinical Vice Chair of the Department of Radiation Oncology at Vanderbilt University Medical Center. He received his B.S. in Physiology and Neurobiology from the University of Maryland, then continued his medical education as a graduate of Vanderbilt’s School of Medicine. He completed his medical internship at Abington Memorial Hospital followed by a residency at the University of Pennsylvania.
Dr. Shinohara’s clinical and research areas of interest are in tumors of the genitourinary system and sarcomas. He has presented at several international meetings, such as the American Society for Radiation Oncology (ASTRO), and has been published in many prominent journals, including Cancer, Cancer Research, and Oncogene.
Dr. Shinohara discusses localized prostate cancer in our webinar, “Treatment Options for Localized Prostate Cancer.”